Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1986 Dec;83(23):9169–9173. doi: 10.1073/pnas.83.23.9169

Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies.

I M Nilsson, E Berntorp, O Zettervall
PMCID: PMC387096  PMID: 3491368

Abstract

An approach to the problem of inducing tolerance in patients with hemophilia complicated by high-responding antibodies is described. Thus, in four patients with severe hemophilia B and high-responding antibodies against factor IX, it has been possible to modify the immune response by giving high doses of intravenous IgG in combination with cyclophosphamide and factor IX, followed by regular factor IX treatment. In three of the patients, the in vivo recovery and half-life of infused factor IX coagulant activity (IX:C) are now normal, while the fourth patient has been converted to a low responder. Hip replacement surgery has been performed successfully in one patient. The tolerant state in these four patients is characterized, and they have all been found to have complexes between factor IX antigen and a "new" antibody without IX:C inhibitory activity. The disappearance rate of the complexed factor IX antigen (i.e., lacking IX:C activity) is considerably prolonged, and the persistence in the circulation of this (probably modified) factor IX molecule may be crucial, since tolerance to factor IX treatment was only induced when immunocomplexes were produced. Since earlier treatment of the patients with cyclophosphamide and factor IX, but without IgG, failed to induce tolerance, it appears to be the IgG that is the prerequisite.

Full text

PDF
9169

Images in this article

9172Image
on p.9172

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allain J. P., Verroust F., Soulier J. P. In vitro and in vivo characterization of factor VIII preparations. Vox Sang. 1980 Feb;38(2):68–80. doi: 10.1111/j.1423-0410.1980.tb02333.x. [DOI] [PubMed] [Google Scholar]
  2. Blatt P. M., White G. C., 2nd, McMillan C. W., Roberts H. R. Treatment of anti-factor VIII antibodies. Thromb Haemost. 1977 Aug 31;38(2):514–523. [PubMed] [Google Scholar]
  3. Brackmann H. H. Induced immunotolerance in factor VIII inhibitor patients. Prog Clin Biol Res. 1984;150:181–195. [PubMed] [Google Scholar]
  4. Briët E., Reisner H. M., Roberts H. R. Inhibitors in Christmas disease. Prog Clin Biol Res. 1984;150:123–139. [PubMed] [Google Scholar]
  5. Giannelli F., Choo K. H., Rees D. J., Boyd Y., Rizza C. R., Brownlee G. G. Gene deletions in patients with haemophilia B and anti-factor IX antibodies. Nature. 1983 May 12;303(5913):181–182. doi: 10.1038/303181a0. [DOI] [PubMed] [Google Scholar]
  6. Giddings J. C., Bloom A. L., Kelly M. A., Spratt H. C. Human factor IX inhibitors: immunochemical characteristics and treatment with activated concentrate. Clin Lab Haematol. 1983;5(2):165–175. doi: 10.1111/j.1365-2257.1983.tb01349.x. [DOI] [PubMed] [Google Scholar]
  7. Grubb A. O. Quantitation of J chain in human biological fluids by a simple immunochemical procedure. Acta Med Scand. 1978;204(6):453–465. doi: 10.1111/j.0954-6820.1978.tb08473.x. [DOI] [PubMed] [Google Scholar]
  8. Hedner U., Nilsson I. M. Induced tolerance in hemophilia patients with antibodies against IX:C. Acta Med Scand. 1983;214(3):191–197. doi: 10.1111/j.0954-6820.1983.tb08594.x. [DOI] [PubMed] [Google Scholar]
  9. Hilgartner M. W., Knatterud G. L. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood. 1983 Jan;61(1):36–40. [PubMed] [Google Scholar]
  10. Holmberg L., Gustavii B., Cordesius E., Kristoffersson A. C., Ljung R., Löfberg L., Strömberg P., Nilsson I. M. Prenatal diagnosis of hemophilia B by an immunoradiometric assay of factor IX. Blood. 1980 Sep;56(3):397–401. [PubMed] [Google Scholar]
  11. Hruby M. A., Schulman I. Failure of combined factor VIII and cyclophosphamide to suppress antibody to factor VIII in hemophilia. Blood. 1973 Dec;42(6):919–923. [PubMed] [Google Scholar]
  12. Kasper C. K., Aledort L., Aronson D., Counts R., Edson J. R., van Eys J., Fratantoni J., Green D., Hampton J., Hilgartner M. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975 Nov 15;34(2):612–612. [PubMed] [Google Scholar]
  13. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  14. Lamme S., Wallmark A., Holmberg L., Nilsson I. M., Sjögren H. O. The use of monoclonal antibodies in measuring factor VIII/von Willebrand factor. Scand J Clin Lab Invest. 1985 Feb;45(1):17–26. doi: 10.3109/00365518509160967. [DOI] [PubMed] [Google Scholar]
  15. Nilsson I. M., Hedner U. Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX. Scand J Haematol. 1976 May;16(5):369–382. doi: 10.1111/j.1600-0609.1976.tb00330.x. [DOI] [PubMed] [Google Scholar]
  16. Nilsson I. M., Jonsson S., Sundqvist S. B., Ahlberg A., Bergentz S. E. A procedure for removing high titer antibodies by extracorporeal protein-A-sepharose adsorption in hemophilia: substitution therapy and surgery in a patient with hemophilia B and antibodies. Blood. 1981 Jul;58(1):38–44. [PubMed] [Google Scholar]
  17. Nilsson I. M., Kirkwood T. B., Barrowcliffe T. W. In vivo recovery of factor VIII: a comparison of one-stage and two-stage assay methods. Thromb Haemost. 1979 Dec 21;42(4):1230–1239. [PubMed] [Google Scholar]
  18. Nilsson I. M., Sundqvist S. B., Freiburghaus C. Extracorporeal protein A-sepharose and specific affinity chromatography for removal of antibodies. Prog Clin Biol Res. 1984;150:225–241. [PubMed] [Google Scholar]
  19. Reisner H. M., Roberts H. R., Krumholz S., Yount W. J. Immunochemical characterization of a polyclonal human antibody to factor IX. Blood. 1977 Jul;50(1):11–19. [PubMed] [Google Scholar]
  20. Rosenblum M. G., Unger B. W., Gutterman J. U., Hersh E. M., David G. S., Frincke J. M. Modification of human leukocyte interferon pharmacology with a monoclonal antibody. Cancer Res. 1985 Jun;45(6):2421–2424. [PubMed] [Google Scholar]
  21. Seifried E., Gaedicke G., Pindur G., Rasche H. The treatment of haemophilia A inhibitor with high dose intravenous immunoglobulin. Blut. 1984 Jun;48(6):397–401. doi: 10.1007/BF00319971. [DOI] [PubMed] [Google Scholar]
  22. Shapiro S. S. Antibodies to blood coagulation factors. Clin Haematol. 1979 Feb;8(1):207–214. [PubMed] [Google Scholar]
  23. Sherman L. A., Goldstein M. A., Sise H. S. Circulating anticoagulant (antifactor 8 treated with immunosuppressive drugs. Thromb Diath Haemorrh. 1969 Apr 30;21(2):249–258. [PubMed] [Google Scholar]
  24. Sultan Y., Kazatchkine M. D., Maisonneuve P., Nydegger U. E. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet. 1984 Oct 6;2(8406):765–768. doi: 10.1016/s0140-6736(84)90701-3. [DOI] [PubMed] [Google Scholar]
  25. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wallmark A., Ljung R., Nilsson I. M., Holmberg L., Hedner U., Lindvall M., Sjögren H. O. Polymorphism of normal factor IX detected by mouse monoclonal antibodies. Proc Natl Acad Sci U S A. 1985 Jun;82(11):3839–3843. doi: 10.1073/pnas.82.11.3839. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. White G. C., 2nd, Taylor R. E., Blatt P. M., Roberts H. R. Treatment of a high titer anti-factor-VIII antibody by continuous factor VIII administration: report of a case. Blood. 1983 Jul;62(1):141–145. [PubMed] [Google Scholar]
  28. Zettervall O., Sundqvist S. B., Nilsson I. M. Characterisation of the tolerant state in a patient with haemophilia B after removal of high-titre factor IX antibodies. Scand J Haematol. 1985 May;34(5):446–454. doi: 10.1111/j.1600-0609.1985.tb00776.x. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES